 Kimi Kondo
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiology | 4 | 2017 | 197 | 0.660 |
Why?
| | Lymphocele | 1 | 2013 | 2 | 0.450 |
Why?
| | Curriculum | 4 | 2018 | 853 | 0.420 |
Why?
| | Surgery, Computer-Assisted | 1 | 2013 | 63 | 0.420 |
Why?
| | Faculty | 1 | 2013 | 131 | 0.400 |
Why?
| | Kidney Neoplasms | 4 | 2016 | 325 | 0.310 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 491 | 0.300 |
Why?
| | Kidney Transplantation | 1 | 2013 | 560 | 0.290 |
Why?
| | Clinical Competence | 1 | 2013 | 918 | 0.270 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 990 | 0.260 |
Why?
| | Ultrasonography, Interventional | 2 | 2016 | 132 | 0.240 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2016 | 39 | 0.240 |
Why?
| | Angiomyolipoma | 2 | 2016 | 18 | 0.240 |
Why?
| | Internship and Residency | 1 | 2013 | 949 | 0.220 |
Why?
| | Diagnostic Imaging | 2 | 2016 | 296 | 0.210 |
Why?
| | Students, Medical | 2 | 2017 | 280 | 0.190 |
Why?
| | Education, Medical, Undergraduate | 2 | 2018 | 179 | 0.160 |
Why?
| | Radiology, Interventional | 1 | 2018 | 28 | 0.160 |
Why?
| | Schools, Medical | 2 | 2018 | 125 | 0.150 |
Why?
| | Vena Cava Filters | 1 | 2017 | 50 | 0.140 |
Why?
| | Thromboembolism | 1 | 2017 | 93 | 0.140 |
Why?
| | Pregnancy, Abdominal | 1 | 2016 | 3 | 0.140 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 37 | 0.140 |
Why?
| | Radiology Information Systems | 1 | 2016 | 31 | 0.140 |
Why?
| | Teaching | 1 | 2018 | 226 | 0.140 |
Why?
| | Biotechnology | 1 | 2016 | 46 | 0.130 |
Why?
| | Laboratories | 1 | 2017 | 95 | 0.130 |
Why?
| | Prosthesis Design | 1 | 2017 | 290 | 0.130 |
Why?
| | Venous Thrombosis | 1 | 2017 | 147 | 0.130 |
Why?
| | Organizational Innovation | 1 | 2016 | 131 | 0.130 |
Why?
| | Cavernous Sinus | 1 | 2015 | 14 | 0.130 |
Why?
| | Hypertension, Portal | 1 | 2016 | 62 | 0.130 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 182 | 0.130 |
Why?
| | Venous Insufficiency | 1 | 2015 | 11 | 0.130 |
Why?
| | Portal Vein | 1 | 2016 | 81 | 0.130 |
Why?
| | Personal Satisfaction | 1 | 2017 | 185 | 0.130 |
Why?
| | Radiography, Interventional | 1 | 2016 | 111 | 0.120 |
Why?
| | Arteriovenous Fistula | 1 | 2015 | 29 | 0.120 |
Why?
| | Methotrexate | 1 | 2016 | 228 | 0.120 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2015 | 51 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 374 | 0.120 |
Why?
| | Radiology Department, Hospital | 1 | 2014 | 19 | 0.120 |
Why?
| | Hernia, Abdominal | 1 | 2013 | 6 | 0.120 |
Why?
| | Ascites | 1 | 2013 | 35 | 0.110 |
Why?
| | Hernia, Inguinal | 1 | 2013 | 27 | 0.110 |
Why?
| | Intestinal Obstruction | 1 | 2013 | 41 | 0.110 |
Why?
| | Embolization, Therapeutic | 1 | 2015 | 181 | 0.110 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2013 | 49 | 0.110 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 38 | 0.110 |
Why?
| | Translocation, Genetic | 1 | 2012 | 94 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2016 | 9165 | 0.100 |
Why?
| | Education, Medical | 1 | 2014 | 224 | 0.090 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 93 | 0.090 |
Why?
| | Disease Progression | 3 | 2013 | 2424 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 827 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2012 | 638 | 0.090 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 225 | 0.090 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2010 | 52 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2016 | 847 | 0.080 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 73 | 0.080 |
Why?
| | Neuroblastoma | 1 | 2010 | 130 | 0.080 |
Why?
| | Liver Neoplasms | 1 | 2013 | 521 | 0.080 |
Why?
| | Piperazines | 1 | 2011 | 313 | 0.080 |
Why?
| | Pyrazoles | 1 | 2012 | 362 | 0.080 |
Why?
| | Pyridines | 1 | 2012 | 425 | 0.080 |
Why?
| | Pyrimidines | 1 | 2011 | 376 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2207 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2009 | 197 | 0.070 |
Why?
| | DNA Methylation | 1 | 2011 | 498 | 0.070 |
Why?
| | United States | 4 | 2018 | 12338 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 788 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4671 | 0.070 |
Why?
| | Anatomic Landmarks | 2 | 2016 | 24 | 0.060 |
Why?
| | Aged | 5 | 2016 | 19299 | 0.060 |
Why?
| | Humans | 15 | 2018 | 115901 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 964 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2409 | 0.050 |
Why?
| | Young Adult | 4 | 2016 | 10517 | 0.040 |
Why?
| | Male | 6 | 2016 | 56127 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2333 | 0.040 |
Why?
| | Female | 8 | 2016 | 60081 | 0.040 |
Why?
| | Intergenerational Relations | 1 | 2017 | 15 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2011 | 1177 | 0.040 |
Why?
| | Forecasting | 1 | 2018 | 332 | 0.040 |
Why?
| | Inventions | 1 | 2016 | 16 | 0.030 |
Why?
| | Career Choice | 1 | 2018 | 182 | 0.030 |
Why?
| | Hemoperitoneum | 1 | 2016 | 13 | 0.030 |
Why?
| | History, 20th Century | 1 | 2017 | 276 | 0.030 |
Why?
| | Device Removal | 1 | 2017 | 128 | 0.030 |
Why?
| | Portography | 1 | 2016 | 13 | 0.030 |
Why?
| | Portal Pressure | 1 | 2016 | 6 | 0.030 |
Why?
| | Pregnancy, Ectopic | 1 | 2016 | 53 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 118 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2016 | 72 | 0.030 |
Why?
| | Operative Time | 1 | 2016 | 109 | 0.030 |
Why?
| | Radiation Exposure | 1 | 2016 | 41 | 0.030 |
Why?
| | Models, Organizational | 1 | 2016 | 142 | 0.030 |
Why?
| | Fluoroscopy | 1 | 2016 | 142 | 0.030 |
Why?
| | Adult | 5 | 2016 | 30817 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2016 | 137 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2016 | 142 | 0.030 |
Why?
| | Program Development | 1 | 2017 | 349 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2016 | 12616 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 491 | 0.030 |
Why?
| | Carbon Dioxide | 1 | 2016 | 210 | 0.030 |
Why?
| | Time Factors | 2 | 2016 | 6186 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2016 | 240 | 0.030 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 48 | 0.030 |
Why?
| | Contrast Media | 1 | 2016 | 366 | 0.030 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 56 | 0.030 |
Why?
| | Middle Aged | 4 | 2016 | 27083 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 839 | 0.030 |
Why?
| | Adolescent | 3 | 2016 | 17956 | 0.030 |
Why?
| | Ultrasonography | 1 | 2016 | 671 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 502 | 0.030 |
Why?
| | Laparoscopy | 1 | 2016 | 400 | 0.030 |
Why?
| | Genes, Neoplasm | 1 | 2011 | 21 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2011 | 64 | 0.020 |
Why?
| | Reoperation | 1 | 2013 | 526 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1843 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2011 | 48 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 636 | 0.020 |
Why?
| | ras Proteins | 1 | 2012 | 137 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 157 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 819 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 228 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 169 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1728 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 8714 | 0.020 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 178 | 0.020 |
Why?
| | Kidney | 1 | 2016 | 1208 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 804 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 526 | 0.020 |
Why?
| | Genome, Human | 1 | 2011 | 374 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 754 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1493 | 0.020 |
Why?
| | Nephrectomy | 1 | 2010 | 150 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 557 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 733 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 263 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 609 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 290 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1221 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 2814 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1444 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1391 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2655 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 5090 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 862 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 2749 | 0.010 |
Why?
| | Pregnancy | 1 | 2016 | 5555 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 6438 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4122 | 0.010 |
Why?
| | Infant | 1 | 2016 | 8002 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 9177 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 3342 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1359 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3370 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1891 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3087 | 0.010 |
Why?
| | Child | 1 | 2016 | 18557 | 0.010 |
Why?
|
|
Kondo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|